(Q37333908)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

title

Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Adil Daud

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

8

Pietro Quaglino

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

4

Alain Algazi

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

10

Susana Ortiz-Urda

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

author name string

Igor Vujic

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Matthew Gubens

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Sara Alcántara Luna

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Kevin Lin

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

Klemens Rappersberger

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

language of work or name

English

0 references

publication date

1 November 2015

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

volume

151

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

issue

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

page(s)

1206-1212

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

20 February 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

The blockade of immune checkpoints in cancer immunotherapy

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Treatment and side effect management of CTLA-4 antibody therapy in metastatic melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

PD-1 and PD-1 ligands: from discovery to clinical application

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Cancer immunoediting from immune surveillance to immune escape

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Rates of cutaneous reactions to drugs.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Surface antigens of melanocytes and melanomas. Markers of melanocyte differentiation and melanoma subsets

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Antigens of melanocytes and melanoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Cutaneous reactions to chemotherapeutic drugs and targeted therapy for cancer: Part II. Targeted therapy.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Factors associated with response to high-dose interleukin-2 in patients with metastatic melanoma

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Skin reactions in a subset of patients with stage IV melanoma treated with anti-cytotoxic T-lymphocyte antigen 4 monoclonal antibody as a single agent

2 September 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=5061067

Vitiligo is an independent favourable prognostic factor in stage III and IV metastatic melanoma patients: results from a single-institution hospital-based observational cohort study

20 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26222619

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Vitiligo in patients with metastatic melanoma: a good prognostic sign

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26222619

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Prognostic significance of hypopigmentation in malignant melanoma

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/26222619

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1001/JAMADERMATOL.2015.1916

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:26222619%20AND%20SRC:MED&resulttype=core&format=json

20 February 2020

1 reference